Recent News

• 03.06.2025 - Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
• 03.06.2025 - Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
• 02.25.2025 - Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
• 02.25.2025 - Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
• 01.06.2025 - Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
• 01.06.2025 - Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
• 11.20.2024 - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
• 11.20.2024 - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Recent Filings

• 03.06.2025 - EX-99.1 EX-99.1
• 03.06.2025 - 8-K Current report
• 02.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.25.2025 - 8-K Current report
• 02.25.2025 - EX-99.1 EX-99.1
• 02.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 01.17.2025 - 8-K Current report
• 01.08.2025 - 3 Initial statement of beneficial ownership of securities